The use of multi-omics data and approaches in breast cancer immunotherapy: a review.
Antigens, Neoplasm
/ genetics
Breast Neoplasms
/ diagnosis
Combined Modality Therapy
/ methods
Computational Biology
/ methods
Disease Management
Disease Susceptibility
Female
Gene Expression Profiling
/ methods
Humans
Immunotherapy
/ adverse effects
Neoplasm Staging
Proteomics
/ methods
Treatment Outcome
bioinformatics
breast cancer
computational biology
immunotherapy
multi-omics data
neoantigen
omics
Journal
Future oncology (London, England)
ISSN: 1744-8301
Titre abrégé: Future Oncol
Pays: England
ID NLM: 101256629
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
pubmed:
29
8
2020
medline:
16
7
2021
entrez:
29
8
2020
Statut:
ppublish
Résumé
Breast cancer is projected to be the most common cancer in women in 2020 in the USA. Despite high remission rates treatment side effects remain an issue, hence the interest in novel approaches such as immunotherapies which aim to utilize patients' immune systems to target cancer cells. This review summarizes the basics of breast cancer including staging and treatment options, followed by a discussion on immunotherapy, including immune checkpoint blockade. After this, examples of the role of omics-type data and computational biology/bioinformatics in breast cancer are explored. Ultimately, there are several promising areas to investigate such as the prediction of neoantigens and the use of multi-omics data to direct research, with noted appropriate in clinical trial design in terms of end points.
Identifiants
pubmed: 32857605
doi: 10.2217/fon-2020-0143
doi:
Substances chimiques
Antigens, Neoplasm
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM